Top News

Spectrum Pharmaceuticals Buys Remaining Rights To Compound

Irvine-based Spectrum Pharmaceuticals has acquired the remaining rights to RenaZorb, the firm's nanotechnology compound being used for treating hyperphosphatemia in patients with chronic kidney disease. The firm said it is paying $750,000 in restricted common stock for the rights to owner Altair Nanotechnologies. Spectrum had acquired a worldwide license to the compound in 2005.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel